Is prophylactic deworming recommended for healthy adults, and what regimen should be used for those with travel to endemic areas, occupational exposure, or immunosuppression?

Prophylactic Deworming in Adults

Direct Recommendation

Prophylactic deworming is not routinely recommended for healthy adults in non-endemic settings, but empiric treatment with a single dose of albendazole 400 mg plus ivermectin 200 μg/kg is strongly recommended for adults with prolonged travel to endemic areas (≥6 years residence), occupational soil exposure, or planned immunosuppression. 1, 2

---

Clinical Context and Rationale

When Prophylactic Deworming IS Recommended

High-risk populations who warrant empiric treatment include:

• Long-term residents of endemic areas (≥6 years): Standard stool microscopy detects parasites in only ~1.4% of samples, making empiric treatment more practical than repeated testing 1, 2

• Travelers with high-risk exposures: Those with barefoot soil contact, consumption of unwashed produce, or prolonged exposure in tropical endemic regions should receive empiric treatment even with negative stool examinations 1, 2

• Pre-immunosuppression screening: Adults who will undergo corticosteroid therapy, chemotherapy, or other immunosuppressive treatment must be screened or empirically treated for Strongyloides stercoralis to prevent fatal hyperinfection syndrome 2, 3

• Occupational exposure: Workers with regular soil contact in endemic areas benefit from periodic empiric treatment 1

• Unexplained eosinophilia: Adults with eosinophilia and negative stool studies should receive empiric combination therapy 1, 2

---

Recommended Treatment Regimen

Standard Empiric Protocol

The recommended regimen is:

• Albendazole 400 mg orally as a single dose
• PLUS Ivermectin 200 μg/kg orally as a single dose 1, 2

This combination provides:

• Coverage for hookworm (Ancylostoma duodenale, Necator americanus), Ascaris lumbricoides, and Enterobius vermicularis 1, 3
• Critical protection against Strongyloides stercoralis, which can cause fatal hyperinfection in immunosuppressed patients 2, 3
• Single-dose convenience with high efficacy, eliminating the need for repeated stool testing with poor sensitivity 1

---

Critical Safety Precautions Before Ivermectin

Mandatory Screening Requirements

Before administering ivermectin, you MUST exclude:

• Loa loa infection: Screen anyone with travel to Central or West Africa; microfilaremia >8,000 mf/mL carries high risk of severe encephalitis or death 2

• Onchocerciasis: Exclusion required to avoid severe Mazzotti reactions 2

Administration details:

• Ivermectin should be taken on an empty stomach with water to maximize absorption 2
• No renal dose adjustment needed; safety of multiple doses in severe liver disease not established 2

---

When Prophylactic Deworming Is NOT Recommended

Routine prophylaxis should be avoided in:

• Healthy adults without endemic exposure: No evidence supports routine deworming in low-risk populations 1, 2

• Short-term travelers (<6 years) without high-risk exposures: Risk-benefit ratio does not favor empiric treatment 1

• Asymptomatic household contacts of infected individuals: Focus on infection-prevention measures rather than empiric treatment 2

• Acute watery diarrhea without recent travel: Empiric antiparasitic therapy not indicated unless patient is immunocompromised 2

---

Special Populations

Immunocompromised Patients

For adults on or planning immunosuppression:

• Screen for Strongyloides before starting corticosteroids or other immunosuppressive therapy 2, 3
• If screening unavailable or negative with high clinical suspicion, give empiric albendazole 400 mg plus ivermectin 200 μg/kg 2
• Never start corticosteroids without first excluding or treating Strongyloides infection 3

Pregnancy and Lactation

• Ivermectin is considered low-risk based on limited human data and probably compatible with breastfeeding 2
• Albendazole has embryotoxicity concerns in animal studies; risk-benefit assessment required 2

---

Follow-Up and Monitoring

Post-treatment considerations:

• Repeat dosing: Consider a second dose of albendazole 400 mg plus ivermectin 200 μg/kg one month after symptom resolution to eradicate adult worms that matured after initial treatment 1, 3

• Persistent symptoms: If symptoms continue, repeat stool examination 2-3 weeks after therapy 1

• Routine monitoring: Not required for standard two-dose albendazole regimen 3

• Extended therapy monitoring: If treatment exceeds 14 days, obtain complete blood count and liver function tests every 2 weeks due to hepatotoxicity risk (16% incidence) and leukopenia (10% incidence) 2, 3

---

Prevention of Reinfection

Key preventive measures include:

• Hand hygiene and wearing shoes in endemic areas 1
• Screening and treating household contacts in endemic settings 1
• Avoiding barefoot soil contact and consuming only washed produce in endemic regions 1

---

Common Pitfalls to Avoid

1. Do not skip Loa loa screening before ivermectin in anyone with Central/West African travel history—this can be fatal 2

2. Do not use albendazole alone for empiric treatment in high-risk populations—the combination with ivermectin is essential for Strongyloides coverage 1, 2

3. Do not start immunosuppression without first addressing potential Strongyloides infection 2, 3

4. Do not rely on stool microscopy alone in endemic-exposed populations—sensitivity is only ~1.4% 1, 2

5. Do not confuse treatment regimens: For confirmed hookworm, albendazole 400 mg should be repeated after 2 weeks; for empiric prophylaxis, the single-dose combination is sufficient 1, 3